

CLAIM AMENDMENTS

1. (Currently Amended) A method of chemosensitizing ~~chemosensitization of~~ tumor tissue comprising administration of a chemotherapeutic agent and a composition comprising cationic liposomes which consists of cationic lipid, phosphatidylcholine and cholesterol and having encapsulated therein as least one oligonucleotide, wherein said oligonucleotide targets raf.
2. (Currently Amended) ~~A method in~~ The method of claim 1, wherein the oligonucleotide ranges in size from 10 to 40 nucleotides and phosphorothioated at only the end nucleotides.
3. (Currently Amended) ~~A method in~~ The method of claim 1, wherein the oligonucleotide comprises 10 to 40 nucleotides and all of its bases are phosphorothioated.
4. (Currently Amended) ~~A method in~~ The method of claim 1, wherein the oligonucleotide ~~ranges in size~~ comprises 10 to 40 nucleotides, wherein all of its bases are modified in a chimeric form.
5. (Currently Amended) ~~A method in~~ The method of claim 1, wherein the oligonucleotide is administered intravenously.
6. (Currently Amended) ~~A method in~~ The method of claim 1, wherein the oligonucleotide is administered directly to the target tissue.
7. (Currently Amended) ~~A method in~~ The method of claim 1, wherein the oligonucleotide is administered into the arterial supply to the target tissue.
8. (Currently Amended) ~~The composition~~ method of claim 1, wherein said oligonucleotide is an antisense DNA.
9. (Currently Amended) The method of claim 1, wherein the oligonucleotide is of the formula 5'-GTGCTCCATTGATGC-3' (~~Seq. ID No:~~ SEQ ID NO: 1) and only the end bases are ~~phosphorothiotated~~ phosphorothioated.

10. (Canceled)
11. (Canceled)
12. (Currently Amended) The method ~~in~~ of claim 1, wherein the chemotherapeutic agent is an alkylating agent, an antimetabolite, a natural product, a hormone or an antagonist.
13. (Currently Amended) The method of claim 1, wherein the chemotherapeutic agent is a platinum coordination complex, an anthracenedione, a substituted urea, a methylhydrazine derivative, an adrenocortical suppressant, a small molecule inhibitor, a peptide, an antibody, or ~~an~~ a tyrosine kinase inhibitor.
14. (Currently Amended) The method ~~in~~ of claim 1, wherein the chemotherapeutic agent is epirubicin, doxorubicin, docetaxel, or paclitaxel.
15. (Currently Amended) The method ~~in~~ of claim 1, wherein the chemotherapeutic agent is cisplatin or mitoxantrone.
16. (Currently Amended) The method ~~in~~ of claim 1, wherein the chemotherapeutic agent is gemcitabine.
17. (Currently Amended) The method of claim 1, wherein the tumor tissue is caused by cancer is ~~leukemia, lymphoma, myeloma, carcinoma or sarcoma.~~
18. (Currently Amended) The method of claim 1, wherein the oligonucleotide is administered before or after the chemotherapeutic agent.
19. (Currently Amended) The method of claim 1, wherein several different ~~of~~ oligonucleotides are administered before or after the chemotherapeutic agent.
20. (Currently Amended) The method of claim 1, wherein the oligonucleotide is administered before or after more than one chemotherapeutic agent.
21. (Currently Amended) The method of claim 1, wherein the oligonucleotide is administered before or after a combination of radiation and a chemotherapeutic agent.

22. (Currently Amended) The method of claim 1, ~~where-in~~ wherein more than one ~~oligonucleotides-oligonucleotide are~~ is administered before or after a combination of radiation and a chemotherapeutic agent.
23. (New) The method of claim 17, wherein the cancer is selected from a group consisting of leukemia, lymphoma, myeloma, carcinoma or sarcoma.